International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis

Documenti analoghi

• Real‐World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease
  di: Yoshito Nishimura, et al.
  Pubblicazione: (2026)
• Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance Study
  di: Yoshito Nishimura, et al.
  Pubblicazione: (2025)
• Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy Subtype
  di: Stephanie Quon, et al.
  Pubblicazione: (2026)
• Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns
  di: Mizuna Otsuka, et al.
  Pubblicazione: (2025)
• Idiopathic Multicentric Castleman Disease— TAFRO : A Potentially Curable Disease?
  di: Lu Zhang, et al.
  Pubblicazione: (2026)